Stryker Corporation (NYSE:SYK) Shares Acquired by Bailard Inc.

Bailard Inc. increased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 8.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,703 shares of the medical technology company's stock after purchasing an additional 2,185 shares during the quarter. Bailard Inc.'s holdings in Stryker were worth $10,312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SYK. Elefante Mark B bought a new stake in shares of Stryker during the 4th quarter valued at about $337,000. Mogy Joel R Investment Counsel Inc. lifted its position in Stryker by 3.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after purchasing an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. boosted its position in Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after buying an additional 3,341 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of Stryker in the first quarter worth about $1,840,000. Finally, Mar Vista Investment Partners LLC grew its position in shares of Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after buying an additional 8,353 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

NYSE:SYK traded down $0.06 during mid-day trading on Friday, hitting $388.84. The company's stock had a trading volume of 1,716,294 shares, compared to its average volume of 1,354,042. The business's fifty day moving average is $385.51 and its two-hundred day moving average is $377.73. The stock has a market cap of $148.42 billion, a price-to-earnings ratio of 52.55, a PEG ratio of 2.95 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. Stryker Corporation has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.50 earnings per share. Analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is presently 45.41%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director owned 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SYK shares. Roth Mkm boosted their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research report on Monday, May 5th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $428.55.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.